AXIM appoints Blake N. Schroeder as director to fill vacancy, effective Jan 6, 2022

AXIM BIOTECHNOLOGIES, INC.

Schroeder replaces Mauricio Javier Gatto-Bellora, appointed by written consent of Series C preferred stockholder.
Schroeder serves as CEO and Chairman of Medical Marijuana, Inc., which holds ~16.4% of AXIM common stock.
He formerly served as COO of Forevergreen International and held roles at MonaVie; holds a J.D. and B.S. in Finance.
No related-party transactions or arrangements exist between Schroeder and AXIM.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Mauricio Javier Gatto-Bellora

Director

AXIM · AXIM BIOTECHNOLOGIES, INC.

Successor: Blake N. Schroeder
Filed: January 12, 2022, 6:59 PM ET

consented by written consent in lieu of a meeting appointing Blake N. Schroeder to fill the director seat vacated by the resignation of Mauricio Javier Gatto-Bellora.

Appointed

Blake N. Schroeder

Director

AXIM · AXIM BIOTECHNOLOGIES, INC.

Effective: 2022-01-06
Filed: January 12, 2022, 6:59 PM ET

consented by written consent in lieu of a meeting appointing Blake N. Schroeder to fill the director seat vacated by the resignation of Mauricio Javier Gatto-Bellora.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Mauricio Javier Gatto-Bellora resigned as Director at AXIM BIOTECHNOLOGIES, INC..

Action: resigned
Role: Director

Exact text from the filing

consented by written consent in lieu of a meeting appointing Blake N. Schroeder to fill the director seat vacated by the resignation of Mauricio Javier Gatto-Bellora.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Blake N. Schroeder was appointed as Director at AXIM BIOTECHNOLOGIES, INC..

Action: appointed
Role: Director

Exact text from the filing

consented by written consent in lieu of a meeting appointing Blake N. Schroeder to fill the director seat vacated by the resignation of Mauricio Javier Gatto-Bellora.

View on SEC.gov

AXIM BIOTECHNOLOGIES, INC. filing history →

Source: SEC EDGAR

accession 0001096906-22-000092

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.